New cell therapy takes aim at Hard-to-Treat blood cancer
NCT ID NCT07493135
First seen Mar 25, 2026 · Last updated May 07, 2026 · Updated 9 times
Summary
This early-phase study tests a new treatment called IMV102 in 30 people with multiple myeloma that has returned or not responded to at least three prior therapies. Participants receive a single infusion of their own modified immune cells. The main goal is to check safety, and researchers will also monitor how well the treatment controls the cancer over 24 months.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing GoBroad Boren Hospital
RECRUITINGBeijing, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Renji Hospital, Shanghai Jiao Tong University School of Medicine
NOT_YET_RECRUITINGShanghai, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The second affiliated hospital of Chongqing medical university
NOT_YET_RECRUITINGChongqing, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Zhengzhou Yihe Hospital
NOT_YET_RECRUITINGZhengzhou, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.